![](https://www.evorabio.com/wp-content/uploads/2020/03/cropped-LogoEvora_white_S.png)
Novel immunomodulatory peptides in respiratory inflammation and beyond
Our lead programme focuses on pleiotropic upstream inhibition of TLR4-mediated inflammatory cascades, for over-the-board anti-inflammatory properties.
A receptor-specific, pleiotropic and pathway-agnostic drug holds significant potential in multiple inflammatory diseases, where TLR4 plays a pivotal role at the onset of the disease as well as in preventing its resolution.
We target indications where an immunomodulatory drug is preferred to steroid-based immunosuppressive approaches.
EVORA develops bioactive peptides competitively binding to intracellular domains of TLR4, thus preventing dimerization of the receptor which is required to trigger inflammatory cascades.
In-vitro data confirms the pleiotropic nature of our peptide’s action, as well as its ability to block both IFN-1 and NF-KB pathways.
In-vivo data in lung inflammation models in mice exhibits reduced secretion of pro-inflammatory cytokines and upregulation of pro-inflammatory cytokines.
Development Pipeline
![](https://www.evorabio.com/wp-content/uploads/2024/06/pipeline_EVORA_JUN2024-1024x475.png)
Management
![](https://www.evorabio.com/wp-content/uploads/2020/10/LANVIN-12_BW-e1603795129430-300x300.jpg)
Hadrien Lanvin, MSc, CEO
![](https://www.evorabio.com/wp-content/uploads/2021/07/AnnaK_2_BW-300x300.jpg)
Anna Kostrzak, PhD, Head of R&D
Directors
![](https://www.evorabio.com/wp-content/uploads/2024/06/Remi_Gloecker_sqr_260.jpg)
Rémi Gloeckler, PhD
![](https://www.evorabio.com/wp-content/uploads/2020/10/LANVIN-12_BW-e1603795129430-300x300.jpg)
Hadrien Lanvin, MSc, CEO
![](https://www.evorabio.com/wp-content/uploads/2024/06/Philippe_rousseau-300x300.jpeg)
Philippe Rousseau, MSc
![](https://www.evorabio.com/wp-content/uploads/2024/06/Bruno_tocque_BW-300x300.jpg)
Bruno Tocque, PhD
Partners Network
Supported by
© EVORA Biosciences 2024